Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant® (emapalumab) for ...
A klímaváltozás mára stratégiai gazdasági kérdéssé vált, amelynek hatásai az agráriumban jelentkeznek a legközvetlenebbül. A ...
EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 ---- Phase 3 PREVAIL CVOT overall event rate ...
WILMINGTON, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- UniFirst Corporation (NYSE: UNF) (“UniFirst” or the “Company”) today reported results for its fiscal 2026 first quarter ended November 29, 2025.
Every weekday, NPR's best political reporters are there to explain the big news coming out of Washington and the campaign trail. They don't just tell you what happened. They tell you why it matters.
Assistive devices like lower-limb prostheses and exoskeletons have the potential to enhance the quality of life for a wide range of individuals. A key challenge in realizing the full potential of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback